



Media:

Laura Carabello

lcaravello@cpronline.com

201.641.1911 x12

ImpediMed's SOZO® Digital Health Platform Voted Among Top Five Finalists for Southern California ABBY Awards

Richard Carreon, managing director and CEO, to present at 19th Innovations in Healthcare Awards, Dec. 5, 2018, Long Beach Airport Marriott Hotel

Brisbane, Australia and Carlsbad, CA – November 27, 2018 – [ImpediMed](#) Limited (ASX: IPD), a global provider of medical technology to non-invasively measure, monitor and manage tissue composition and fluid status using bioimpedance spectroscopy (BIS), announces that its SOZO® Digital Health Platform has been voted among the top five finalists for [ABL Organization's 19th Innovations in Healthcare ABBY Awards](#) in the category of Innovative Health IT or Digital Health Technology. Richard Carreon, managing director and CEO, ImpediMed, will present key information about SOZO, a leading, non-invasive and FDA-cleared BIS digital health platform that measures, monitors and manages fluid accumulation in patients with certain conditions resulting from cancer treatment, such as [lymphedema](#) (LE) and heart failure (HF).

“This recognition further elevates the importance of SOZO to enhance cancer survivorship,” says Carreon. “It is breakthrough technology that provides physicians with easy access to an unprecedented level of information and data without the need for an invasive procedure. With increased adoption in healthcare systems nationwide, and with new research validating its effectiveness, an even greater number of cancer survivors can benefit with better health outcomes and improved quality of life.”

Carreon points to the recently published MD Anderson [study](#) to assess the validity of L-Dex BIS measurements for evaluating the effectiveness of interventions to treat lymphedema. Using ImpediMed technology, researchers conclude that the L-Dex correlates most closely with all measures and is the recommended metric when using BIS. Findings support the adjunctive use

of the L-Dex ratio with limb volume measurements for objective diagnosis, evaluation of lymphedema severity, longitudinal serial evaluation of lymphedema, and response to conservative and surgical interventions.

About ImpediMed

Founded and headquartered in Brisbane, Australia, with U.S. and European operations, ImpediMed is the world leader in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of tissue composition and fluid status. ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications, including heart failure and lymphedema, sold in select markets globally. Visit www.impedimed.com.